A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects

Trial Profile

A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs BMS 986166 (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 21 Nov 2017 Status changed from active, no longer recruiting to completed.
    • 01 Nov 2017 Planned End Date changed from 27 Oct 2017 to 7 Nov 2017.
    • 01 Nov 2017 Planned primary completion date changed from 26 Oct 2017 to 7 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top